The drug is already approved in many countries for other lymphoma conditions and is marketed as Epkinly in the U.S. and ...
Nivolumab plus AVD significantly improves PFS compared to brentuximab vedotin plus AVD in advanced-stage classic Hodgkin lymphoma, with a 91% vs 82% 3-year PFS rate. The PFS benefit of nivolumab plus ...
Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...
AbbVie today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging ...
Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
Dr. Ian Flinn, chief scientific officer at Tennessee Oncology and One Oncology in Nashville, Tennessee, explains Lunsumio ...
Pharmaceutical drugs developed by two local companies received approvals in the European Union last month. On Dec. 12, Culver ...
Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...
Zacks Investment Research on MSN
INCY's phase III Monjuvi study meets key goals in first-line lymphoma
Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...
Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.
Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and reduce chemotherapy toxicity. The development of treatments beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback